Reata Pharmaceuticals

Reata Pharmaceuticals, Inc.
Nasdaq: RETA
IndustryBiotechnology
Founded1 January 2002 
FateAcquired by Biogen
Revenue US $26.52 million (2019)
US $53.59 million (2018)
Owner
Websitewww.reatapharma.com

Reata Pharmaceuticals, Inc. is a pharmaceutical company based in Plano, Texas. Founded in 2002, it is primarily focused on investigating experimental oral antioxidative and anti-inflammatory drugs, which dually activate the antioxidative transcription factor Nrf2 and inhibit the pro-inflammatory transcription factor NF-κB. The last CEO of Reata Pharmaceuticals was J. Warren Huff.

In July 2023, it was announced Reata had been acquired by the Cambridge, Massachusetts-headquartered multinational biotechnology company, Biogen for nearly $6.5 billion. The purchase was completed on September 26 and Reata stock was delisted from the Nasdaq.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.